Cover Image

Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine

Show other versions (1)

Mesenchymal stromal cells (MSCs) are promising cell therapy candidates. Clinical application is considered safe. However, minor side effects have included thromboembolism and instant blood-mediated inflammatory reactions suggesting an effect of MSC infusion on hemostasis. Previous studies focusing o...

Full description

Saved in:
Bibliographic Details
Main Authors: Netsch, Philipp (Author) , Elvers-Hornung, Susanne (Author) , Uhlig, Stefanie (Author) , Klüter, Harald (Author) , Huck, Volker (Author) , Janetzko, Karin (Author) , Wuchter, Patrick (Author) , Bugert, Peter (Author) , Bieback, Karen (Author)
Format: Article (Journal)
Language:English
Published: 4 July 2018
In: Stem cell research & therapy
Year: 2018, Volume: 9, Pages: 1-17
ISSN:1757-6512
DOI:10.1186/s13287-018-0936-8
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s13287-018-0936-8
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13287-018-0936-8
Get full text
Author Notes:P. Netsch, S. Elvers-Hornung, S. Uhlig, H. Klüter, V. Huck, F. Kirschhöfer, G. Brenner-Weiß, K. Janetzko, H. Solz, P. Wuchter, P. Bugert and K. Bieback
Description
Summary:Mesenchymal stromal cells (MSCs) are promising cell therapy candidates. Clinical application is considered safe. However, minor side effects have included thromboembolism and instant blood-mediated inflammatory reactions suggesting an effect of MSC infusion on hemostasis. Previous studies focusing on plasmatic coagulation as a secondary hemostasis step detected both procoagulatory and anticoagulatory activities of MSCs. We now focus on primary hemostasis and analyzed whether MSCs can promote or inhibit platelet activation.
Item Description:Gesehen am 26.07.2018
Physical Description:Online Resource
ISSN:1757-6512
DOI:10.1186/s13287-018-0936-8

Similar Items